本次会议的亮点很多，ELCC是多学科的会议。生物标志物研究方面有了新进展，研究者不断发现新的生物标志物；免疫疗法发展显示出其有非常好的前景；外科手术技术不断进步（包括早期肺癌手术）；肺癌筛查项目进一步完善；相关人员致力于戒烟工作以减少肺癌患病率；检测肺癌风险因素以提高肺癌筛查率。肺癌多学科治疗方面取得重要进展：包括靶向治疗、手术、生物标志物、生物学研究等领域；在肺癌患者血浆循环DNA检测、循环肿瘤细胞检测方面，ELCC会议讲者呈现了原著论文（original papers）。

　　欧洲肺癌大会在2015年成为年会（过去是双年会），每年的ELCC会议都会呈现新的内容，虽然距离上次ELCC会议仅一年，今年的ELCC会议呈现许多研究新进展，特别是抗PD-1和PD-L1疗法研究进展激动人心。

访谈原文

　　Oncology Frontier: As a Chair of ELCC 2015， could you please summarize the highlights of ELCC 2015 for the Chinese oncologist?

　　《肿瘤瞭望》：作为2015年ELCC的主席，请你为中国肿瘤医生总结2015年ELCC的会议亮点？

　　Dr. Grunenwald: Firstly， I am very pleased here to see a lot of people coming here from Asia. As we are in Europe and this is a European conference. As a European， and as a surgeon， I am very happy to see surgeons coming particularly from Asia， from China. So， it is a pleasure for us to welcome our colleagues. As an international organization， we aspire for people to come from afar.

　　Grunenwald博士：首先，我很高兴看到亚洲医生能参加本次欧洲肺癌大会。作为一个欧洲人，作为一个外科医生，我很高兴地看到来自亚洲、特别是来自中国的外科医生。世界各地的同侪聚集一堂让我们感到荣幸。作为一个国际组织，我们十分渴望你们能不辞万里来参加本次会议。

　　Highlights of this conference are multiple as it is a multidisciplinary congress. We have the development of biomarkers and found new biomarkers every day. We have the development of immunotherapy， and it is extremely promising. We have developments in surgery as well in the early stages. We are refining the lung cancer screening programs. We are working on smoking cessation to diminish the prevalence of this horrible disease in the future. We are working on detecting the best patient risks to be screened for lung cancer.

　　本次会议的亮点很多，ELCC是多学科的会议。我们对生物标志物的研究有了新进展，并不断发现新的生物标志物；免疫疗法发展显示出其非常有前景。外科手术技术不断进步（包括早期肺癌手术）。我们进一步完善肺癌筛查项目，致力于戒烟工作以减少肺癌患病率；检测肺癌早期风险因素以提高肺癌筛查率。

　　Also， I think there is important development in the possibility for the different category of medical doctors to unify their efforts: targeted therapies， surgeries， biomarkers， and biology. For example， we have original papers on circulating DNA in the plasma of the patients， on urinary， on discovering circulating DNA， and on circulating tumor cells. We have new papers on these and it’s very promising for the future.

　　在肺癌多学科治疗方面取得重要进展：包括靶向治疗、手术、生物标志物、生物学研究。在肺癌患者血浆循环DNA检测、循环肿瘤细胞检测方面，ELCC会议讲者呈现了原著论文（original papers）。

　　Oncology Frontier:  The European Lung Cancer Conference (ELCC) will become an annual meeting as of 2015. Is there anything new in the ELCC 2015?

　　《肿瘤瞭望》：欧洲肺癌大会在2015年成为年会（过去是双年会），ELCC 2015有何创新之处？

　　Dr. Grunenwald: Yes， there were some new developments that were presented here even though we just met one year ago.  I think we will have some occasion to present new insights and developments every year. What is really newly presented here is the PD-1 and PD-L1 development. I think it’s something extremely exciting for us.

　　Grunenwald博士：我想我们每年的ELCC会议都会呈现新的内容，虽然距离上次ELCC会议仅一年，今年的ELCC会议呈现许多研究新进展。特别是抗PD-1和PD-L1疗法研究进展激动人心。